| 摘要 |
<p>Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidine compounds having the structural formula (I) or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl or heteroaryl, cycloalkenyl, -C(=CH2)CH3, -Ca"C-CH3, -CH=C(CH3)2, X is alkylene, -C(O)CH2- or -C(O)N(R2)CH2-;Y is -N(R2)CH2CH2N(R3)-, -OCH2CH2N(R2)-, -O-, -S-, -CH2S-, -(CH2)2-N(R2)-, or optionally substituted divalent heteroaryl, piperidinyl or piperazinyl; and Z is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl or R6-C(O)-; or when Y is formula (II) Z is also R6-SO2-, R7-N(R8)-C(O)-, R7-N(R8)-C(S)- or R6OC(O)-;or when Y is 4-piperidinyl, Z can be phenylamino or pyridylamino; or Z and Y together are substituted piperidinyl, substituted pyrrolidinyl or substituted phenyl; R14 is H, halogen or optionally substituted alkyl; and Q, Q1, m, n, R2, R3, R4, R6, R7 and R8 are as defined in the specification are disclosed. These compounds are suitable for treating stroke, depression, cognitive diseases and neurodegenerative diseases such as Parkinson's disease, senile dementia and psychoses of organic origin.</p> |
